|
 
Last update: |
 |
|
|
19-Mar-2015
|
 |
|
|
Arch Hellen Med, 32(2), March-April 2015, 158-166 REVIEW Prevention of microvascular diabetic complications by fenofibrate A. Koutsovasilis,1 A.K. Papa zafiropoulou,2 S.I. Pappas,1 S. Bousboulas1 |
Microvascular complications are common in patients with type 2 diabetes mellitus. According to the results of recent studies (ADVANCE, VADT, ACCORD), achievement of glycemic control and blood pressure targets have only minor impact on microvascular complications. In 2005, the FIELD study showed that fenofibrate reduces the need for laser treatment of retinopathy and slows the progress of renal dysfunction. Furthermore, the FIELD eye sub-study concluded that fenofibrate reduces the risk of retinopathy and its progression. A later analysis of the FIELD study concluded that fenofibrate also reduces the risk of non-traumatic amputation in patients with diabetes. The ACCORD study produced similar results, showing that fenofibrate use significantly reduced the progression of retinopathy and albuminuria, independently of its effect on lipids. The results of these studies confirm the important role of fenofibrate in the prevention of significant microvascular diabetic complications.
Key words: Diabetic complications, Fenofibrate, Microvascular disease, Type 2 diabetes mellitus.
